Antifungal drugs market was valued at over USD 15.5 billion in 2023 and is anticipated to grow at a CAGR of over 3.7% between 2024 and 2032 owing to increasing prevalence of fungal infections.
Antibacterial activities against E. coli, B. cereus, P. aeruginosa and S. aureus are expressed in terms of EC50 (µM) values with corresponding 95% confidence interval (CI) range. The human CAMP LL-37
High-throughput phenotypic screening against yeast Saccharomyces cerevisiae revealed a series of triazolo-pyrimidine-sulfonamide compounds with broad-spectrum antifungal activity, no significant cytot